Shares of Cell MedX Corp. (OTCMKTS:CMXC – Get Free Report) shot up 16.3% on Monday . The company traded as high as $0.4770 and last traded at $0.4770. 500 shares were traded during trading, a decline of 98% from the average session volume of 20,342 shares. The stock had previously closed at $0.41.
Cell MedX Stock Up 16.3%
The business’s 50 day moving average is $0.38 and its 200-day moving average is $0.35.
Cell MedX Company Profile
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual.
Recommended Stories
- Five stocks we like better than Cell MedX
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Wall Street ‘Sleeper Stock’ Could Become #1 Stock of 2026
- Trump’s Hand-Written Letter Will Shock his Haters
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Cell MedX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cell MedX and related companies with MarketBeat.com's FREE daily email newsletter.
